Edesa Biotech Inc
EDSA
查看详细走势图
1.120USD
+0.020+1.82%
收盘 02/06, 16:00（美东）报价延迟15分钟
8.00M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.82%
5天
-4.27%
1月
-27.27%
6月
-46.41%
今年开始到现在
-21.13%
1年
-41.41%
查看详细走势图
TradingKey Edesa Biotech Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Edesa Biotech Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名137/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Edesa Biotech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Edesa Biotech Inc亮点
亮点风险
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
估值合理
公司最新PE估值-0.88，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值37.60K
分析师目标
根据
2
位分析师
买入
评级
11.000
目标均价
+909.17%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Edesa Biotech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Edesa Biotech Inc简介
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
公司代码EDSA
公司Edesa Biotech Inc
CEONijhawan (Pardeep)
网址https://www.edesabiotech.com/
相关品种
